Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:02 18/07/2024 am IST			5-day change	1st Jan Change
42.48 ^USD	-0.21%		+3.53%	-5.12%

09/07	AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT	MT
08/07	Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans	CI

Drug Response Dx GmbH announced that it has received funding from High-Tech Gründerfonds Management GmbH and Qiagen NV.

January 07, 2013 at 09:30 am IST

Drug Response Dx GmbH announced that it has received its seed round of funding from new investors Qiagen NV and High-Tech Gründerfonds Management GmbH on January 7, 2013. Qiagen NV has made a strategic equity investment in the company. The terms of the transaction were not disclosed. High-Tech Gründerfonds Management GmbH invested through its fund High-Tech Gründerfonds II GmbH und Co. KG.

On January 7, 2013, Drug Response Dx GmbH closed the transaction.

Latest news about Qiagen N.V.

AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT	09/07	MT
Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans	09/07	CI
Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	27/06	MT
Qiagen Seeks M&A	21/06	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	21/06
Sartorius on the downswing again - low since 2020 is approaching	19/06	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	19/06	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	18/06	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	18/06	MT
QIAGEN NV : Gets a Neutral rating from UBS	18/06	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	18/06	ZD
QIAGEN NV : Berenberg remains its Buy rating	18/06	ZD
Frankfurt shares close: Dax recovers	17/06	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	17/06
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	17/06	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	17/06	MT
Qiagen eyes sales growth of 7% per year until 2028	17/06	RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret	14/06	CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook	07/06	MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System	07/06	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024	07/06	CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe	06/06	CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care	03/06	CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	31/05	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	31/05	MT

Chart Qiagen N.V.

Duration

Period

More charts

Company Profile

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 07:02 pm IST

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

42.48 USD

Average target price

49.73 USD

Spread / Average Target

+17.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-5.12%	942.41Cr
MODERNA, INC.	+24.74%	4.75TCr
IQVIA HOLDINGS INC.	-0.47%	4.2TCr
LONZA GROUP AG	+43.96%	4.16TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.04TCr
ICON PUBLIC LIMITED COMPANY	+17.96%	2.76TCr
CELLTRION, INC.	-4.47%	2.87TCr
UNITED THERAPEUTICS CORPORATION	+50.73%	1.47TCr
MEDPACE HOLDINGS, INC.	+42.56%	1.35TCr
BIO-TECHNE CORPORATION	+1.46%	1.23TCr

Other Biotechnology & Medical Research